{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:20Z","timestamp":1793239400764,"version":"4.5.0"},"reference-count":323,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["R01AI186632"],"award-info":[{"award-number":["R01AI186632"]}]},{"name":"NIH","award":["K24AI134359"],"award-info":[{"award-number":["K24AI134359"]}]},{"name":"NIH","award":["P30AI042853"],"award-info":[{"award-number":["P30AI042853"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40265-025-02181-1","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:21:27Z","timestamp":1747027287000},"page":"883-909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Advanced HIV in the Modern Era"],"prefix":"10.1007","volume":"85","author":[{"given":"Joseph M.","family":"Garland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Mayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3659-1108","authenticated-orcid":false,"given":"Rami","family":"Kantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2181_CR1","unstructured":"UNAIDS. Fact Sheet 2024. Global HIV statistics [cited 2025 January 15]. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf."},{"issue":"4599","key":"2181_CR2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","volume":"220","author":"F Barre-Sinoussi","year":"1983","unstructured":"Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868\u201371.","journal-title":"Science"},{"issue":"4648","key":"2181_CR3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1126\/science.6200936","volume":"224","author":"RC Gallo","year":"1984","unstructured":"Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984;224(4648):500\u20133.","journal-title":"Science"},{"issue":"1","key":"2181_CR4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cpt.1284","volume":"105","author":"C Flexner","year":"2019","unstructured":"Flexner C. Modern human immunodeficiency virus therapy: progress and prospects. Clin Pharmacol Ther. 2019;105(1):61\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2181_CR5","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2352-3018(20)30232-0","volume":"8","author":"M Dybul","year":"2021","unstructured":"Dybul M, Attoye T, Baptiste S, Cherutich P, Dabis F, Deeks SG, et al. The case for an HIV cure and how to get there. Lancet HIV. 2021;8(1):e51\u20138.","journal-title":"Lancet HIV."},{"issue":"7751","key":"2181_CR6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5Delta32\/Delta32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244\u20138.","journal-title":"Nature"},{"issue":"7","key":"2181_CR7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G Hutter","year":"2009","unstructured":"Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K, et al. Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2181_CR8","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"BO Jensen","year":"2023","unstructured":"Jensen BO, Knops E, Cords L, Lubke N, Salgado M, Busman-Sahay K, et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5Delta32\/Delta32 allogeneic hematopoietic stem cell transplantation. Nat Med. 2023;29(3):583\u20137.","journal-title":"Nat Med"},{"issue":"6","key":"2181_CR9","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","volume":"186","author":"J Hsu","year":"2023","unstructured":"Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023;186(6):1115-26.e8.","journal-title":"Cell"},{"issue":"7","key":"2181_CR10","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMc2312556","volume":"390","author":"JK Dickter","year":"2024","unstructured":"Dickter JK, Aribi A, Cardoso AA, Gianella S, Gendzekhadze K, Li S, et al. HIV-1 remission after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2024;390(7):669\u201371.","journal-title":"N Engl J Med"},{"issue":"4","key":"2181_CR11","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3018(24)00028-6","volume":"11","author":"M Maheu-Giroux","year":"2024","unstructured":"Maheu-Giroux M, Mishra S. Evidence with 95\u201395-95 that ambitious is feasible. Lancet HIV. 2024;11(4):e203\u20134.","journal-title":"Lancet HIV."},{"issue":"4","key":"2181_CR12","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1016\/S2352-3018(24)00003-1","volume":"11","author":"M Mine","year":"2024","unstructured":"Mine M, Stafford KA, Laws RL, Marima R, Lekone P, Ramaabya D, et al. Progress towards the UNAIDS 95\u201395-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey. Lancet HIV. 2024;11(4):e245\u201354.","journal-title":"Lancet HIV."},{"key":"2181_CR13","unstructured":"HIV.gov. U.S. Statistics. [cited 2024 December 28]. https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics."},{"issue":"11","key":"2181_CR14","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s10461-021-03497-1","volume":"25","author":"WW Darrow","year":"2021","unstructured":"Darrow WW. The first 40 years of AIDS: promising programs, limited success. AIDS Behav. 2021;25(11):3449\u201371.","journal-title":"AIDS Behav"},{"key":"2181_CR15","unstructured":"CDC. HIV and Black\/African American people in the U.S. [cited 2025 January 15]. https:\/\/www.cdc.gov\/nchhstp\/newsroom\/fact-sheets\/hiv\/black-african-american-factsheet.html."},{"issue":"1","key":"2181_CR16","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1038\/s41467-021-24673-w","volume":"12","author":"JV Lazarus","year":"2021","unstructured":"Lazarus JV, Safreed-Harmon K, Kamarulzaman A, Anderson J, Leite RB, Behrens G, et al. Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nat Commun. 2021;12(1):4450.","journal-title":"Nat Commun"},{"issue":"21","key":"2181_CR17","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1056\/NEJMp1904113","volume":"380","author":"WM El-Sadr","year":"2019","unstructured":"El-Sadr WM, Mayer KH, Rabkin M, Hodder SL. AIDS in America\u2014back in the headlines at long last. N Engl J Med. 2019;380(21):1985\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"2181_CR18","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3018(21)00101-6","volume":"8","author":"LG Bekker","year":"2021","unstructured":"Bekker LG, Beyrer C. Africa and AIDS: still much work to be done. Lancet HIV. 2021;8(6):e315\u20136.","journal-title":"Lancet HIV."},{"issue":"2","key":"2181_CR19","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2165","volume":"31","author":"H Newman","year":"2021","unstructured":"Newman H, Hardie D. HIV-1 viral load testing in resource-limited settings: Challenges and solutions for specimen integrity. Rev Med Virol. 2021;31(2): e2165.","journal-title":"Rev Med Virol"},{"issue":"1","key":"2181_CR20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1186\/s12889-022-13504-2","volume":"22","author":"MD Pham","year":"2022","unstructured":"Pham MD, Nguyen HV, Anderson D, Crowe S, Luchters S. Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead\u2014a systematic review. BMC Public Health. 2022;22(1):1203.","journal-title":"BMC Public Health"},{"key":"2181_CR21","unstructured":"DHHS. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. [cited 2025 January 20]. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections\/toxoplasma-gondii?view=full."},{"key":"2181_CR22","unstructured":"BHIVA. BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022 (2023 interim update) [cited 2024 November 16]. https:\/\/www.bhiva.org\/file\/63513a1745ea9\/BHIVA-guidelines-on-antiretroviral-treatment-for-adults-living-with-HIV-1-2022.pdf."},{"key":"2181_CR23","unstructured":"EACS. European AIDS Clinical Society. Guidelines Version 12.0. 2023 [cited 2023 December 23]. https:\/\/www.eacsociety.org\/media\/guidelines-12.0.pdf."},{"issue":"1","key":"2181_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA Panel. JAMA. 2023;329(1):63\u201384.","journal-title":"JAMA"},{"key":"2181_CR25","unstructured":"WHO. Consolidated guidelines on HIV testing services for a changing epidemic. [cited 2024 December 28]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/329966\/WHO-CDS-HIV-19.31-eng.pdf?utm_source=chatgpt.com."},{"key":"2181_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae479","author":"M Horberg","year":"2024","unstructured":"Horberg M, Thompson M, Agwu A, Colasanti J, Haddad M, Jain M, et al. Primary care guidance for providers of care for persons with human immunodeficiency virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae479.","journal-title":"Clin Infect Dis"},{"key":"2181_CR27","unstructured":"WHO. Providing care to people with advanced HIV disease who are seriously ill. 2023 [cited 2025 January 15]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/366628\/9789240068650-eng.pdf."},{"issue":"6","key":"2181_CR28","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1007\/s10461-024-04298-y","volume":"28","author":"I Portilla-Tamarit","year":"2024","unstructured":"Portilla-Tamarit I, Rubio-Aparicio M, Fuster-RuizdeApodaca MJ, Portilla-Tamarit J, Reus S, Portilla J. Health-related quality of life in people with advanced HIV disease, from 1996 to 2021: systematic review and meta-analysis. AIDS Behav. 2024;28(6):1978\u201398.","journal-title":"AIDS Behav"},{"issue":"1","key":"2181_CR29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12981-020-00296-x","volume":"17","author":"AT Boyd","year":"2020","unstructured":"Boyd AT, Oboho I, Paulin H, Ali H, Godfrey C, Date A, et al. Addressing advanced HIV disease and mortality in global HIV programming. AIDS Res Ther. 2020;17(1):40.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"2181_CR30","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","volume":"10","author":"A Trickey","year":"2023","unstructured":"Trickey A, Sabin CA, Burkholder G, Crane H, d\u2019Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295\u2013307.","journal-title":"Lancet HIV."},{"issue":"4","key":"2181_CR31","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/jcm10040716","volume":"10","author":"J Portilla-Tamarit","year":"2021","unstructured":"Portilla-Tamarit J, Reus S, Portilla I, Fuster Ruiz-de-Apodaca MJ, Portilla J. Impact of advanced HIV disease on quality of life and mortality in the era of combined antiretroviral treatment. J Clin Med. 2021;10(4):716.","journal-title":"J Clin Med"},{"issue":"9","key":"2181_CR32","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","volume":"72","author":"MW Tang","year":"2012","unstructured":"Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1-25.","journal-title":"Drugs"},{"issue":"5","key":"2181_CR33","doi-asserted-by":"crossref","first-page":"135965352312011","DOI":"10.1177\/13596535231201162","volume":"28","author":"A Carr","year":"2023","unstructured":"Carr A, Mackie NE, Paredes R, Ruxrungtham K. HIV drug resistance in the era of contemporary antiretroviral therapy: a clinical perspective. Antivir Ther. 2023;28(5):13596535231201162.","journal-title":"Antivir Ther"},{"key":"2181_CR34","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4848","volume":"6","author":"M Zazzi","year":"2018","unstructured":"Zazzi M, Hu H, Prosperi M. The global burden of HIV-1 drug resistance in the past 20 years. PeerJ. 2018;6: e4848.","journal-title":"PeerJ"},{"issue":"2","key":"2181_CR35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","volume":"68","author":"HF Gunthard","year":"2019","unstructured":"Gunthard HF, Calvez V, Paredes R, Pillay D, Shafer RW, Wensing AM, et al. Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel. Clin Infect Dis. 2019;68(2):177\u201387.","journal-title":"Clin Infect Dis"},{"issue":"17","key":"2181_CR36","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","volume":"377","author":"C Beyrer","year":"2017","unstructured":"Beyrer C, Pozniak A. HIV drug resistance\u2014an emerging threat to epidemic control. N Engl J Med. 2017;377(17):1605\u20137.","journal-title":"N Engl J Med"},{"key":"2181_CR37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","volume":"46","author":"DS Clutter","year":"2016","unstructured":"Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292\u2013307.","journal-title":"Infect Genet Evol"},{"issue":"4","key":"2181_CR38","first-page":"559","volume":"30","author":"AM Wensing","year":"2022","unstructured":"Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Gunthard HF, Paredes R, et al. 2022 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2022;30(4):559\u201374.","journal-title":"Top Antivir Med."},{"issue":"1","key":"2181_CR39","first-page":"43","volume":"20","author":"CA Boucher","year":"2018","unstructured":"Boucher CA, Bobkova MR, Hung CC, Kaiser R, Marcelin AG, Streinu-Cercel A, et al. State of the art in HIV drug resistance: surveillance and regional gaps. AIDS Rev. 2018;20(1):43\u201357.","journal-title":"AIDS Rev"},{"issue":"10","key":"2181_CR40","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350(10):1023\u201335.","journal-title":"N Engl J Med"},{"key":"2181_CR41","unstructured":"Shafer R. The Stanford HIV Sequence Database. [cited 2024 November 14]. http:\/\/hivdb.stanford.edu."},{"key":"2181_CR42","unstructured":"WHO. HIV drug resistance. 2024 [cited 2025 January 21]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-drug-resistance."},{"issue":"4","key":"2181_CR43","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3390\/biomedicines12040915","volume":"12","author":"MM Apetroaei","year":"2024","unstructured":"Apetroaei MM, Velescu BS, Nedea MII, Dinu-Pirvu CE, Draganescu D, Faca AI, et al. The phenomenon of antiretroviral drug resistance in the context of human immunodeficiency virus treatment: dynamic and ever evolving subject matter. Biomedicines. 2024;12(4):915.","journal-title":"Biomedicines."},{"issue":"3","key":"2181_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004724","volume":"4","author":"DE Bennett","year":"2009","unstructured":"Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE. 2009;4(3): e4724.","journal-title":"PLoS ONE"},{"issue":"1","key":"2181_CR45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","volume":"75","author":"PL Tzou","year":"2020","unstructured":"Tzou PL, Rhee SY, Descamps D, Clutter DS, Hare B, Mor O, et al. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. J Antimicrob Chemother. 2020;75(1):170\u201382.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2181_CR46","volume":"11","author":"WL Yang","year":"2015","unstructured":"Yang WL, Kouyos RD, Boni J, Yerly S, Klimkait T, Aubert V, et al. Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds. PLoS Pathog. 2015;11(3): e1004722.","journal-title":"PLoS Pathog"},{"issue":"5","key":"2181_CR47","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/civ400","volume":"61","author":"RD Kouyos","year":"2015","unstructured":"Kouyos RD, Gunthard HF. Editorial commentary: The irreversibility of HIV drug resistance. Clin Infect Dis. 2015;61(5):837\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2181_CR48","doi-asserted-by":"crossref","first-page":"ofab587","DOI":"10.1093\/ofid\/ofab587","volume":"9","author":"V Novitsky","year":"2022","unstructured":"Novitsky V, Steingrimsson J, Gillani FS, Howison M, Aung S, Solomon M, et al. Statewide longitudinal trends in transmitted HIV-1 drug resistance in Rhode Island, USA. Open Forum Infect Dis. 2022;9(1):ofab587.","journal-title":"Open Forum Infect Dis"},{"key":"2181_CR49","unstructured":"WHO. HIV drug resistance report 2021. [cited 2024 Nonvember 12]. https:\/\/www.who.int\/publications\/i\/item\/9789240038608."},{"key":"2181_CR50","unstructured":"WHO. HIVResNet. Global HIV drug resistance network. [cited 2025 January 20]. https:\/\/www.who.int\/groups\/who-hivresnet."},{"issue":"10","key":"2181_CR51","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/cid\/civ102","volume":"60","author":"R Kantor","year":"2015","unstructured":"Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, et al. Pretreatment HIV drug resistance and HIV-1 subtype C are independently associated with virologic failure: results from the multinational PEARLS (ACTG A5175) clinical trial. Clin Infect Dis. 2015;60(10):1541\u20139.","journal-title":"Clin Infect Dis"},{"key":"2181_CR52","unstructured":"WHO. HIV drug resistance\u2014brief report 2024. [cited 2024 November 12]. https:\/\/www.who.int\/publications\/i\/item\/9789240086319."},{"key":"2181_CR53","unstructured":"Aung S, Novitsky V, Steingrimsson J, Gillani FS, Howison M, Nagel K, et al. Statewide trends of acquired HIV-1 drug resistance in Rhode Island over 2004-2021. J Infect Dis. 2024 (in press)."},{"issue":"5","key":"2181_CR54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","volume":"16","author":"J Gregson","year":"2016","unstructured":"Gregson J, Tang M, Ndembi N, Hamers RL, Rhee SY, Marconi VC, et al. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis. 2016;16(5):565\u201375.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2181_CR55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077691","volume":"8","author":"V von Wyl","year":"2013","unstructured":"von Wyl V, Klimkait T, Yerly S, Nicca D, Furrer H, Cavassini M, et al. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV cohort study. PLoS ONE. 2013;8(10): e77691.","journal-title":"PLoS ONE"},{"issue":"2","key":"2181_CR56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-151-2-200907210-00003","volume":"151","author":"FJ Palella Jr","year":"2009","unstructured":"Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009;151(2):73\u201384.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2181_CR57","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","volume":"74","author":"F Sanger","year":"1977","unstructured":"Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74(12):5463\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2181_CR58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/v13020340","volume":"13","author":"R Kantor","year":"2021","unstructured":"Kantor R. Next generation sequencing for HIV-1 drug resistance testing-A special issue walkthrough. Viruses. 2021;13(2):340.","journal-title":"Viruses"},{"issue":"4","key":"2181_CR59","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","volume":"44","author":"CJ Petropoulos","year":"2000","unstructured":"Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44(4):920\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"2181_CR60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jcv.2018.05.008","volume":"105","author":"R Reece","year":"2018","unstructured":"Reece R, Delong A, Matthew D, Tashima K, Kantor R. Accumulated pre-switch resistance to more recently introduced one-pill-once-a-day antiretroviral regimens impacts HIV-1 virologic outcome. J Clin Virol. 2018;105:11\u20137.","journal-title":"J Clin Virol"},{"issue":"17","key":"2181_CR61","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/QAD.0000000000001964","volume":"32","author":"R Kantor","year":"2018","unstructured":"Kantor R, DeLong A, Schreier L, Reitsma M, Kemboi E, Orido M, et al. HIV-1 second-line failure and drug resistance at high-level and low-level viremia in Western Kenya. AIDS. 2018;32(17):2485\u201396.","journal-title":"AIDS"},{"issue":"7","key":"2181_CR62","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/v15071416","volume":"15","author":"V Novitsky","year":"2023","unstructured":"Novitsky V, Nyandiko W, Vreeman R, DeLong AK, Howison M, Manne A, et al. Added value of next generation sequencing in characterizing the evolution of HIV-1 drug resistance in Kenyan youth. Viruses. 2023;15(7):1416.","journal-title":"Viruses"},{"issue":"10","key":"2181_CR63","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","volume":"71","author":"TS Boender","year":"2016","unstructured":"Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, et al. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. J Antimicrob Chemother. 2016;71(10):2918\u201327.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2181_CR64","volume":"35","author":"C Chu","year":"2022","unstructured":"Chu C, Armenia D, Walworth C, Santoro MM, Shafer RW. Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells. Clin Microbiol Rev. 2022;35(4): e0005222.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2181_CR65","doi-asserted-by":"crossref","first-page":"ofz533","DOI":"10.1093\/ofid\/ofz533","volume":"7","author":"KE Ellis","year":"2020","unstructured":"Ellis KE, Nawas GT, Chan C, York L, Fisher J, Connick E, et al. Clinical outcomes following the use of archived proviral HIV-1 DNA Genotype to guide antiretroviral therapy adjustment. Open Forum Infect Dis. 2020;7(1):ofz533.","journal-title":"Open Forum Infect Dis"},{"issue":"7","key":"2181_CR66","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/QAD.0000000000002879","volume":"35","author":"DD Richman","year":"2021","unstructured":"Richman DD. Disregarding drug resistance mutations without peril. AIDS. 2021;35(7):1135\u20136.","journal-title":"AIDS"},{"issue":"4","key":"2181_CR67","doi-asserted-by":"crossref","first-page":"ofad146","DOI":"10.1093\/ofid\/ofad146","volume":"10","author":"D Curanovic","year":"2023","unstructured":"Curanovic D, Martens SK, Rodriguez MA, Hammill HA, Petropoulos CJ, Walworth CM. HIV-1 DNA testing in viremic patients identifies more drug resistance than HIV-1 RNA testing. Open Forum Infect Dis. 2023;10(4):ofad146.","journal-title":"Open Forum Infect Dis"},{"key":"2181_CR68","unstructured":"WHO. Global action plan on HIV drug resistance 2017-2021. [cited 2023 December 26] . http:\/\/who.int\/hiv\/pub\/drugresistance\/hivdr-action-plan-2017-2021\/en\/."},{"key":"2181_CR69","unstructured":"WHO. HIVResNet HIV drug resistance laboratory operational framework. 2020 [cited 2025 January 20]. https:\/\/www.who.int\/publications\/i\/item\/978-92-4-000987-5."},{"key":"2181_CR70","unstructured":"WHO. Laboratory-based survey of acquired HIV drug resistance using remnant viral load specimens. 2021 [cited 2024 January 25]. https:\/\/www.who.int\/publications\/i\/item\/9789240025417."},{"key":"2181_CR71","unstructured":"WHO. HIV drug resistance strategy: 2021 update. [cited 2023 September 28]. https:\/\/www.who.int\/publications\/i\/item\/9789240030565."},{"issue":"Suppl 4","key":"2181_CR72","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.1093\/cid\/cis207","volume":"54","author":"DE Bennett","year":"2012","unstructured":"Bennett DE, Jordan MR, Bertagnolio S, Hong SY, Ravasi G, McMahon JH, et al. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries. Clin Infect Dis. 2012;54(Suppl 4):S280\u20139.","journal-title":"Clin Infect Dis"},{"key":"2181_CR73","unstructured":"WHO. Global report on early warning indicators of HIV drug resistance: technical report. 2016 [cited 2025 January 20]. http:\/\/apps.who.int\/iris\/bitstream\/10665\/246219\/1\/9789241511179-eng.pdf."},{"issue":"11","key":"2181_CR74","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(24)00151-4","volume":"5","author":"M Nair","year":"2024","unstructured":"Nair M, Gettins L, Fuller M, Kirtley S, Hemelaar J. Global and regional genetic diversity of HIV-1 in 2010\u201321: systematic review and analysis of prevalence. Lancet Microbe. 2024;5(11): 100912.","journal-title":"Lancet Microbe."},{"issue":"11","key":"2181_CR75","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/infdis\/jiad327","volume":"228","author":"A Williams","year":"2023","unstructured":"Williams A, Menon S, Crowe M, Agarwal N, Biccler J, Bbosa N, et al. Geographic and population distributions of human immunodeficiency virus (HIV)-1 and HIV-2 circulating subtypes: a systematic literature review and meta-analysis (2010\u20132021). J Infect Dis. 2023;228(11):1583\u201391.","journal-title":"J Infect Dis"},{"issue":"3","key":"2181_CR76","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2666-5247(20)30006-9","volume":"1","author":"MC Puertas","year":"2020","unstructured":"Puertas MC, Ploumidis G, Ploumidis M, Fumero E, Clotet B, Walworth CM, et al. Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report. Lancet Microbe. 2020;1(3):e130\u20135.","journal-title":"Lancet Microbe."},{"issue":"3","key":"2181_CR77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/hiv.12411","volume":"18","author":"A Judd","year":"2017","unstructured":"Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, et al. Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe. HIV Med. 2017;18(3):171\u201380.","journal-title":"HIV Med"},{"issue":"8","key":"2181_CR78","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3018(20)30205-8","volume":"7","author":"S Raymond","year":"2020","unstructured":"Raymond S, Piffaut M, Bigot J, Cazabat M, Montes B, Bertrand K, et al. Sexual transmission of an extensively drug-resistant HIV-1 strain. Lancet HIV. 2020;7(8):e529\u201330.","journal-title":"Lancet HIV."},{"issue":"13","key":"2181_CR79","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/QAD.0000000000001920","volume":"32","author":"KK Seatla","year":"2018","unstructured":"Seatla KK, Avalos A, Moyo S, Mine M, Diphoko T, Mosepele M, et al. Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana. AIDS. 2018;32(13):1899\u2013902.","journal-title":"AIDS"},{"issue":"11","key":"2181_CR80","doi-asserted-by":"crossref","first-page":"ofaa456","DOI":"10.1093\/ofid\/ofaa456","volume":"7","author":"L Galli","year":"2020","unstructured":"Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, et al. Burden of disease in PWH harboring a multidrug-resistant virus: data from the PRESTIGIO Registry. Open Forum Infect Dis. 2020;7(11):ofaa456.","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"2181_CR81","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/2325957415596229","volume":"14","author":"JM Volpe","year":"2015","unstructured":"Volpe JM, Ward DJ, Napolitano L, Phung P, Toma J, Solberg O, et al. Five antiretroviral drug class-resistant HIV-1 in a treatment-naive patient successfully suppressed with optimized antiretroviral drug selection. J Int Assoc Provid AIDS Care. 2015;14(5):398\u2013401.","journal-title":"J Int Assoc Provid AIDS Care."},{"issue":"1","key":"2181_CR82","doi-asserted-by":"crossref","first-page":"885","DOI":"10.4102\/sajhivmed.v20i1.885","volume":"20","author":"C Chimbetete","year":"2019","unstructured":"Chimbetete C, Chirimuta L, Pascoe M, Keiser O. A case report of untreatable HIV infection in Harare, Zimbabwe. South Afr J HIV Med. 2019;20(1):885.","journal-title":"South Afr J HIV Med."},{"issue":"3","key":"2181_CR83","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/S2666-5247(20)30058-6","volume":"1","author":"RL Hamers","year":"2020","unstructured":"Hamers RL, Inzaule SC. Pan-resistant HIV-1: what\u2019s next? Lancet Microbe. 2020;1(3):e97\u20138.","journal-title":"Lancet Microbe."},{"key":"2181_CR84","doi-asserted-by":"crossref","first-page":"1133407","DOI":"10.3389\/fmicb.2023.1133407","volume":"14","author":"A Temereanca","year":"2023","unstructured":"Temereanca A, Ruta S. Strategies to overcome HIV drug resistance-current and future perspectives. Front Microbiol. 2023;14:1133407.","journal-title":"Front Microbiol"},{"issue":"Suppl 1","key":"2181_CR85","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1093\/ofid\/ofab466.117","volume":"8","author":"D Curanovic","year":"2021","unstructured":"Curanovic D, Lai D, Petropoulos C, Walworth C. Trends in four-class HIV drug resistance in treatment-experienced patients in the United States. Open Forum Infect Dis. 2021;8(Suppl 1):S71.","journal-title":"Open Forum Infect Dis"},{"issue":"603","key":"2181_CR86","volume":"17","author":"J Nuwagaba","year":"2024","unstructured":"Nuwagaba J, Li JA, Ngo B, Sutton RE. 30 years of HIV therapy: current and future antiviral drug targets. Virology. 2024;17(603): 110362.","journal-title":"Virology"},{"issue":"1","key":"2181_CR87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","volume":"43","author":"L Menendez-Arias","year":"2022","unstructured":"Menendez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16\u201329.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"2181_CR88","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S2352-3018(23)00259-X","volume":"10","author":"R Kantor","year":"2023","unstructured":"Kantor R. INSTI era resistance: emerging concern or marginal issue? Lancet HIV. 2023;10(11):e696\u20138.","journal-title":"Lancet HIV."},{"issue":"3","key":"2181_CR89","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/S2352-3018(22)00327-7","volume":"10","author":"R Kantor","year":"2023","unstructured":"Kantor R, Gupta RK. We should not stop considering HIV drug resistance testing at failure of first-line antiretroviral therapy. Lancet HIV. 2023;10(3):e202\u20138.","journal-title":"Lancet HIV."},{"key":"2181_CR90","unstructured":"USPSTF. HIV infection: Screening. 2019 [cited 2024 January 25]. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/human-immunodeficiency-virus-hiv-infection-screening."},{"key":"2181_CR91","unstructured":"WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021 [cited 2023 December 26]. https:\/\/www.who.int\/publications\/i\/item\/9789240031593."},{"key":"2181_CR92","unstructured":"CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 dependent areas, 2020: National profile. 2020 [cited 2024 January 25]. https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-27-no-3\/content\/national-profile.html."},{"issue":"12","key":"2181_CR93","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.7196\/SAMJ.2017.v107i12.12358","volume":"107","author":"HN Fomundam","year":"2017","unstructured":"Fomundam HN, Tesfay AR, Mushipe SA, Mosina MB, Boshielo CT, Nyambi HT, et al. Prevalence and predictors of late presentation for HIV care in South Africa. S Afr Med J. 2017;107(12):1058\u201364.","journal-title":"S Afr Med J"},{"issue":"2","key":"2181_CR94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/aid.2015.0379","volume":"34","author":"SV Komninakis","year":"2018","unstructured":"Komninakis SV, Mota ML, Hunter JR, Diaz RS. Late presentation HIV\/AIDS is still a challenge in Brazil and worldwide. AIDS Res Hum Retroviruses. 2018;34(2):129\u201331.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"2181_CR95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1293.2010.00857.x","volume":"12","author":"A Antinori","year":"2011","unstructured":"Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61\u20134.","journal-title":"HIV Med"},{"key":"2181_CR96","unstructured":"CDC. HIV data [cited 2024 December 28]. https:\/\/www.cdc.gov\/hiv-data\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/hiv\/statistics\/surveillance\/terms.html."},{"key":"2181_CR97","unstructured":"WHO. The WHO clinical staging system for HIV\/AIDS. 2010 [cited 2024 January 29]. https:\/\/journalofethics.ama-assn.org\/article\/who-clinical-staging-system-hivaids\/2010-03."},{"issue":"2","key":"2181_CR98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e31829cfbfa","volume":"64","author":"C Montlahuc","year":"2013","unstructured":"Montlahuc C, Guiguet M, Abgrall S, Daneluzzi V, de Salvador F, Launay O, et al. Impact of late presentation on the risk of death among HIV-infected people in France (2003\u20132009). J Acquir Immune Defic Syndr. 2013;64(2):197\u2013203.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2181_CR99","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1186\/s12889-016-3477-z","volume":"16","author":"E Raffetti","year":"2016","unstructured":"Raffetti E, Postorino MC, Castelli F, Casari S, Castelnuovo F, Maggiolo F, et al. The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health. 2016;16(1):878.","journal-title":"BMC Public Health"},{"issue":"3","key":"2181_CR100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0b013e32834dcec9","volume":"26","author":"F Nakagawa","year":"2012","unstructured":"Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26(3):335\u201343.","journal-title":"AIDS"},{"issue":"7","key":"2181_CR101","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/QAD.0000000000003511","volume":"37","author":"R Gabert","year":"2023","unstructured":"Gabert R, Lama JR, Valdez R, Dasgupta S, Cabello R, Sanchez H, et al. Acute retroviral syndrome is associated with lower CD4 + T cell nadir and delayed viral suppression, which are blunted by immediate antiretroviral therapy initiation. AIDS. 2023;37(7):1103\u20138.","journal-title":"AIDS"},{"issue":"10","key":"2181_CR102","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/00003246-199510000-00012","volume":"23","author":"C Feeney","year":"1995","unstructured":"Feeney C, Bryzman S, Kong L, Brazil H, Deutsch R, Fritz LC. T-lymphocyte subsets in acute illness. Crit Care Med. 1995;23(10):1680\u20135.","journal-title":"Crit Care Med"},{"issue":"6","key":"2181_CR103","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMp2313777","volume":"390","author":"N Ford","year":"2024","unstructured":"Ford N, Ehrenkranz P, Jarvis J. Advanced HIV as a neglected disease. N Engl J Med. 2024;390(6):487\u20139.","journal-title":"N Engl J Med"},{"key":"2181_CR104","unstructured":"WHO. Guidelines fo managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017 [cited 2025 January 15]. https:\/\/www.who.int\/publications\/i\/item\/9789241550062."},{"issue":"2","key":"2181_CR105","first-page":"95","volume":"11","author":"VMS Brienze","year":"2021","unstructured":"Brienze VMS, Andre JC, Liso E, Louis IV. Cryptococcal Immune reconstitution inflammatory syndrome: from blood and cerebrospinal fluid biomarkers to treatment approaches. Life (Basel). 2021;11(2):95.","journal-title":"Life (Basel)."},{"issue":"4","key":"2181_CR106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(10)70026-8","volume":"10","author":"M Muller","year":"2010","unstructured":"Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251\u201361.","journal-title":"Lancet Infect Dis"},{"key":"2181_CR107","unstructured":"Brust JCM, McGowan JP, Fine SM, Merrick ST, Radix AE, Vail RM, et al. Clinical Guidelines Program. Management of Immune Reconstitution Inflammatory Syndrome (IRIS) 2024 [cited 2025 January 20]. https:\/\/www.hivguidelines.org\/wp-content\/uploads\/2024\/03\/NYSDOH-AI-Management-of-IRIS_3-7-2024.pub-update_3-7-2024_HG.pdf."},{"issue":"5","key":"2181_CR108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005575","volume":"4","author":"A Zolopa","year":"2009","unstructured":"Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;4(5): e5575.","journal-title":"PLoS ONE"},{"issue":"11","key":"2181_CR109","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1086\/652652","volume":"50","author":"AT Makadzange","year":"2010","unstructured":"Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50(11):1532\u20138.","journal-title":"Clin Infect Dis"},{"issue":"26","key":"2181_CR110","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","volume":"370","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"11","key":"2181_CR111","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","volume":"52","author":"ME Torok","year":"2011","unstructured":"Torok ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374\u201383.","journal-title":"Clin Infect Dis"},{"issue":"15","key":"2181_CR112","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/QAD.0b013e32833dfc68","volume":"24","author":"G Meintjes","year":"2010","unstructured":"Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381\u201390.","journal-title":"AIDS"},{"key":"2181_CR113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1479-5876-5-50","volume":"5","author":"J Riddell","year":"2007","unstructured":"Riddell J, Kaul DR, Karakousis PC, Gallant JE, Mitty J, Kazanjian PH. Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. J Transl Med. 2007;5:50.","journal-title":"J Transl Med"},{"issue":"16","key":"2181_CR114","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.32158","volume":"125","author":"AE Coghill","year":"2019","unstructured":"Coghill AE, Han X, Suneja G, Lin CC, Jemal A, Shiels MS. Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base. Cancer. 2019;125(16):2868\u201376.","journal-title":"Cancer"},{"issue":"11","key":"2181_CR115","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","volume":"378","author":"R Yarchoan","year":"2018","unstructured":"Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases. N Engl J Med. 2018;378(11):1029\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"2181_CR116","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/cancers16030546","volume":"16","author":"A Omar","year":"2024","unstructured":"Omar A, Marques N, Crawford N. Cancer and HIV: the molecular mechanisms of the deadly duo. Cancers (Basel). 2024;16(3):546.","journal-title":"Cancers (Basel)."},{"issue":"17","key":"2181_CR117","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","volume":"134","author":"A Noy","year":"2019","unstructured":"Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134(17):1385\u201394.","journal-title":"Blood"},{"issue":"1","key":"2181_CR118","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/17425255.2024.2408004","volume":"21","author":"C Branch","year":"2025","unstructured":"Branch C, Parson-Martinez J, Cory TJ. Drug-drug interactions in HIV-infected patients receiving chemotherapy. Expert Opin Drug Metab Toxicol. 2025;21(1):15\u201327.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"2181_CR119","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000222071.60620.1d","volume":"20","author":"S Loubser","year":"2006","unstructured":"Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20(7):995\u20131002.","journal-title":"AIDS"},{"issue":"3","key":"2181_CR120","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1086\/519164","volume":"196","author":"DM Smith","year":"2007","unstructured":"Smith DM, Wong JK, Shao H, Hightower GK, Mai SH, Moreno JM, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis. 2007;196(3):356\u201360.","journal-title":"J Infect Dis"},{"key":"2181_CR121","unstructured":"WHO. Target product profile for HIV drug resistance tests in low- and middle-income countries: Africa. [cited 2024 November 13]. https:\/\/www.who.int\/publications\/i\/item\/9789240076662."},{"issue":"6","key":"2181_CR122","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","volume":"74","author":"M Alvarez","year":"2019","unstructured":"Alvarez M, Casas P, de Salazar A, Chueca N, Guerrero-Beltran C, Rodriguez C, et al. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. J Antimicrob Chemother. 2019;74(6):1693\u2013700.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2181_CR123","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/jac\/dkad109","volume":"78","author":"C Muccini","year":"2023","unstructured":"Muccini C, Galli L, Sampaolo M, Gianotti N, Castagna A, Canetti D. Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV. J Antimicrob Chemother. 2023;78(5):1314\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"2181_CR124","unstructured":"HRSA. Ryan White HIV\/AIDS Program Services Report (RSR). [cited 2024 May 1]. https:\/\/ryanwhite.hrsa.gov\/grants\/manage\/reporting-requirements\/rsr."},{"issue":"suppl_2","key":"2181_CR125","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1093\/cid\/cix1142","volume":"66","author":"A Siika","year":"2018","unstructured":"Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, Berkley J, et al. Late presentation with HIV in Africa: phenotypes, risk, and risk stratification in the REALITY Trial. Clin Infect Dis. 2018;66(suppl_2):S140\u20136.","journal-title":"Clin Infect Dis"},{"key":"2181_CR126","unstructured":"WHO. The advanced HIV disease research landscape. 2024 [cited 2025 January 15]. https:\/\/iris.who.int\/bitstream\/handle\/10665\/376040\/9789240089020-eng.pdf?sequence=1."},{"issue":"8","key":"2181_CR127","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/hiv.13487","volume":"24","author":"A Lehman","year":"2023","unstructured":"Lehman A, Ellis J, Nalintya E, Bahr NC, Loyse A, Rajasingham R. Advanced HIV disease: a review of diagnostic and prophylactic strategies. HIV Med. 2023;24(8):859\u201376.","journal-title":"HIV Med"},{"issue":"1","key":"2181_CR128","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1186\/s12879-023-08521-4","volume":"23","author":"MK Kitenge","year":"2023","unstructured":"Kitenge MK, Fatti G, Eshun-Wilson I, Aluko O, Nyasulu P. Prevalence and trends of advanced HIV disease among antiretroviral therapy-naive and antiretroviral therapy-experienced patients in South Africa between 2010\u20132021: a systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):549.","journal-title":"BMC Infect Dis"},{"issue":"13","key":"2181_CR129","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0000000000003653","volume":"37","author":"K Francois","year":"2023","unstructured":"Francois K, Van Onacker JD, Jordan MR, Journel I, Buteaue J, Pierre E, et al. First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir\/lamivudine\/dolutegravir use in mothers. AIDS. 2023;37(13):2097\u20139.","journal-title":"AIDS"},{"issue":"10","key":"2181_CR130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1089\/aid.2020.0261","volume":"37","author":"AJ Bailey","year":"2021","unstructured":"Bailey AJ, Rhee SY, Shafer RW. Integrase strand transfer inhibitor resistance in integrase strand transfer inhibitor-naive persons. AIDS Res Hum Retroviruses. 2021;37(10):736\u201343.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"6","key":"2181_CR131","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciab583","volume":"74","author":"RP McClung","year":"2022","unstructured":"McClung RP, Oster AM, Ocfemia MCB, Saduvala N, Heneine W, Johnson JA, et al. Transmitted drug resistance among human immunodeficiency virus (HIV)-1 diagnoses in the United States, 2014\u20132018. Clin Infect Dis. 2022;74(6):1055\u201362.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2181_CR132","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"MS Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493\u2013505.","journal-title":"N Engl J Med"},{"issue":"2","key":"2181_CR133","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","volume":"316","author":"AJ Rodger","year":"2016","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171\u201381.","journal-title":"JAMA"},{"issue":"8","key":"2181_CR134","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(18)30132-2","volume":"5","author":"BR Bavinton","year":"2018","unstructured":"Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438\u201347.","journal-title":"Lancet HIV."},{"key":"2181_CR135","unstructured":"CDC. Undetectable = Untransmittable. 2024 [cited 2025 January 21]. https:\/\/www.cdc.gov\/global-hiv-tb\/php\/our-approach\/undetectable-untransmittable.html."},{"issue":"10400","key":"2181_CR136","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","volume":"402","author":"LN Broyles","year":"2023","unstructured":"Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023;402(10400):464\u201371.","journal-title":"Lancet"},{"issue":"10400","key":"2181_CR137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(23)01519-2","volume":"402","author":"LG Bekker","year":"2023","unstructured":"Bekker LG, Smith P, Ntusi NAB. HIV is sexually untransmittable when viral load is undetectable. Lancet. 2023;402(10400):428\u20139.","journal-title":"Lancet"},{"key":"2181_CR138","volume":"146","author":"KE Darling","year":"2016","unstructured":"Darling KE, Hachfeld A, Cavassini M, Kirk O, Furrer H, Wandeler G. Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. Swiss Med Wkly. 2016;146: w14348.","journal-title":"Swiss Med Wkly"},{"issue":"suppl2","key":"2181_CR139","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/cid\/cix1138","volume":"66","author":"A Calmy","year":"2018","unstructured":"Calmy A, Ford N, Meintjes G. The persistent challenge of advanced HIV disease and AIDS in the era of antiretroviral therapy. Clin Infect Dis. 2018;66(suppl2):S103-SS105.","journal-title":"Clin Infect Dis"},{"key":"2181_CR140","doi-asserted-by":"crossref","first-page":"1201087","DOI":"10.3389\/frph.2023.1201087","volume":"5","author":"K Bouabida","year":"2023","unstructured":"Bouabida K, Chaves BG, Anane E. Challenges and barriers to HIV care engagement and care cascade: viewpoint. Front Reprod Health. 2023;5:1201087.","journal-title":"Front Reprod Health."},{"issue":"12","key":"2181_CR141","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/17512433.2019.1698946","volume":"12","author":"MC Masters","year":"2019","unstructured":"Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol. 2019;12(12):1129\u201343.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"suppl_2","key":"2181_CR142","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/cid\/cix1140","volume":"66","author":"M Osler","year":"2018","unstructured":"Osler M, Hilderbrand K, Goemaere E, Ford N, Smith M, Meintjes G, et al. The continuing burden of advanced HIV disease over 10 years of increasing antiretroviral therapy coverage in South Africa. Clin Infect Dis. 2018;66(suppl_2):S118\u201325.","journal-title":"Clin Infect Dis"},{"issue":"suppl_2","key":"2181_CR143","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1093\/cid\/ciy103","volume":"66","author":"J Ousley","year":"2018","unstructured":"Ousley J, Niyibizi AA, Wanjala S, Vandenbulcke A, Kirubi B, Omwoyo W, et al. High proportions of patients with advanced HIV are antiretroviral therapy experienced: hospitalization outcomes from 2 Sub-Saharan African Sites. Clin Infect Dis. 2018;66(suppl_2):S126\u201331.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2181_CR144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0002457","volume":"3","author":"L Tugume","year":"2023","unstructured":"Tugume L, Semitala FC, Owachi D, Kagimu E, Kamya MR, Meya DB. Clinical characteristics and morbidity among hospitalized adults with advanced HIV disease in Uganda during \u2018test and treat\u2019 era. PLOS Glob Public Health. 2023;3(10): e0002457.","journal-title":"PLOS Glob Public Health."},{"issue":"1","key":"2181_CR145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","volume":"14","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo VJ, et al. Beyond viral suppression of HIV\u2014the new quality of life frontier. BMC Med. 2016;14(1):94.","journal-title":"BMC Med"},{"key":"2181_CR146","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120901395","author":"J Cutrell","year":"2020","unstructured":"Cutrell J, Jodlowski T, Bedimo R. The management of treatment-experienced HIV patients (including virologic failure and switches). Ther Adv Infect Dis. 2020. https:\/\/doi.org\/10.1177\/2049936120901395.","journal-title":"Ther Adv Infect Dis."},{"issue":"10","key":"2181_CR147","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/QAD.0000000000003924","volume":"38","author":"A Trickey","year":"2024","unstructured":"Trickey A, Zhang L, Rentsch CT, Pantazis N, Izquierdo R, Antinori A, et al. Care interruptions and mortality among adults in Europe and North America. AIDS. 2024;38(10):1533\u201342.","journal-title":"AIDS"},{"issue":"10","key":"2181_CR148","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/infdis\/jiz650","volume":"221","author":"HA Mbunkah","year":"2020","unstructured":"Mbunkah HA, Bertagnolio S, Hamers RL, Hunt G, Inzaule S, Rinke De Wit TF, et al. Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naive individuals: a systematic review of detection methods, prevalence, and clinical impact. J Infect Dis. 2020;221(10):1584\u201397.","journal-title":"J Infect Dis"},{"issue":"11","key":"2181_CR149","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3018(18)30177-2","volume":"5","author":"SC Inzaule","year":"2018","unstructured":"Inzaule SC, Hamers RL, Noguera-Julian M, Casadella M, Parera M, Kityo C, et al. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study. Lancet HIV. 2018;5(11):e638\u201346.","journal-title":"Lancet HIV."},{"issue":"9","key":"2181_CR150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004293","volume":"20","author":"SC Inzaule","year":"2023","unstructured":"Inzaule SC, Siedner MJ, Little SJ, Avila-Rios S, Ayitewala A, Bosch RJ, et al. Recommendations on data sharing in HIV drug resistance research. PLoS Med. 2023;20(9): e1004293.","journal-title":"PLoS Med"},{"key":"2181_CR151","unstructured":"Shafer R. Database statistics. [cited 2024 July 11]. https:\/\/hivdb.stanford.edu\/cgi-bin\/Summary.cgi."},{"issue":"8","key":"2181_CR152","doi-asserted-by":"crossref","first-page":"e497","DOI":"10.1016\/S2352-3018(23)00113-3","volume":"10","author":"O Ogbuagu","year":"2023","unstructured":"Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2\/3 trial. Lancet HIV. 2023;10(8):e497\u2013505.","journal-title":"Lancet HIV."},{"issue":"19","key":"2181_CR153","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N Engl J Med. 2022;386(19):1793\u2013803.","journal-title":"N Engl J Med"},{"issue":"13","key":"2181_CR154","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"LG Bekker","year":"2024","unstructured":"Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"2181_CR155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.idc.2024.04.001","volume":"38","author":"Y Li","year":"2024","unstructured":"Li Y, Choudhary M, Mellors JW. The current pipeline of antiretroviral therapy: expanding options and filling gaps. Infect Dis Clin North Am. 2024;38(3):395\u2013408.","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"2181_CR156","doi-asserted-by":"crossref","first-page":"e0342022","DOI":"10.1128\/spectrum.03420-22","volume":"10","author":"J Fokam","year":"2022","unstructured":"Fokam J, Ngoufack Jagni Semengue E, Molimbou E, Etame NK, Santoro MM, Takou D, et al. Evaluation of circulating and archived HIV-1 Integrase drug-resistance variants among patients on third-line ART in Cameroon: implications for dolutegravir-containing regimens in resource-limited settings. Microbiol Spectr. 2022;10(6):e0342022.","journal-title":"Microbiol Spectr."},{"issue":"11","key":"2181_CR157","doi-asserted-by":"crossref","first-page":"e733","DOI":"10.1016\/S2352-3018(23)00228-X","volume":"10","author":"T Loosli","year":"2023","unstructured":"Loosli T, Hossmann S, Ingle SM, Okhai H, Kusejko K, Mouton J, et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV. 2023;10(11):e733\u201341.","journal-title":"Lancet HIV."},{"issue":"3","key":"2181_CR158","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/QAD.0000000000004049","volume":"39","author":"CV Vollmond","year":"2025","unstructured":"Vollmond CV, Tetens MM, Gerstoft J, Kronborg G, Johansen IS, Larsen CS, et al. Bipolar disorder in people with HIV. AIDS. 2025;39(3):253\u201360.","journal-title":"AIDS"},{"issue":"2","key":"2181_CR159","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/QAI.0b013e3181cbd21e","volume":"54","author":"R Zajdenverg","year":"2010","unstructured":"Zajdenverg R, Podsadecki TJ, Badal-Faesen S, Andrade-Villanueva J, Gathe J, Mingrone H, et al. Similar safety and efficacy of once- and twice-daily lopinavir\/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. J Acquir Immune Defic Syndr. 2010;54(2):143\u201351.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9534","key":"2181_CR160","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0140-6736(06)69154-X","volume":"368","author":"CB Hicks","year":"2006","unstructured":"Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet. 2006;368(9534):466\u201375.","journal-title":"Lancet"},{"issue":"9","key":"2181_CR161","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/630210","volume":"49","author":"Y Yazdanpanah","year":"2009","unstructured":"Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir\/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2181_CR162","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","volume":"21","author":"C Katlama","year":"2007","unstructured":"Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21(4):395\u2013402.","journal-title":"AIDS"},{"issue":"6","key":"2181_CR163","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e3280b07b47","volume":"21","author":"R Haubrich","year":"2007","unstructured":"Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, et al. Week 24 efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21(6):F11\u20138.","journal-title":"AIDS"},{"issue":"9581","key":"2181_CR164","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(07)61049-6","volume":"370","author":"JV Madruga","year":"2007","unstructured":"Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370(9581):49\u201358.","journal-title":"Lancet"},{"issue":"3","key":"2181_CR165","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/v15030762","volume":"15","author":"PF Salvo","year":"2023","unstructured":"Salvo PF, Farinacci D, Ciccullo A, Borghi V, Rusconi S, Saracino A, et al. Efficacy of dolutegravir versus darunavir in antiretroviral first-line regimens according to resistance mutations and viral subtype. Viruses. 2023;15(3):762.","journal-title":"Viruses"},{"issue":"6","key":"2181_CR166","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1016\/S2352-3018(22)00092-3","volume":"9","author":"NI Paton","year":"2022","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 2022;9(6):e381\u201393.","journal-title":"Lancet HIV."},{"issue":"4","key":"2181_CR167","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385(4):330\u201341.","journal-title":"N Engl J Med"},{"issue":"10","key":"2181_CR168","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/INF.0000000000003647","volume":"41","author":"K Steegen","year":"2022","unstructured":"Steegen K, Levin L, Evans D, Technau KG, Hans L. Minimal cross-resistance to tenofovir in children and adolescents failing ART makes them eligible for tenofovir-lamivudine-dolutegravir treatment. Pediatr Infect Dis J. 2022;41(10):827\u201334.","journal-title":"Pediatr Infect Dis J"},{"key":"2181_CR169","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.05.012","volume":"132","author":"NA Margot","year":"2016","unstructured":"Margot NA, Liu Y, Miller MD, Callebaut C. High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. Antiviral Res. 2016;132:50\u20138.","journal-title":"Antiviral Res"},{"issue":"4","key":"2181_CR170","volume":"95","author":"S Cox","year":"2023","unstructured":"Cox S, Margot N, Callebaut C. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R. J Med Virol. 2023;95(4): e28723.","journal-title":"J Med Virol"},{"issue":"12","key":"2181_CR171","doi-asserted-by":"crossref","first-page":"908","DOI":"10.7326\/M15-0949","volume":"163","author":"KT Tashima","year":"2015","unstructured":"Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, et al. HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: a randomized, controlled trial. Ann Intern Med. 2015;163(12):908\u201317.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2181_CR172","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/phar.2914","volume":"44","author":"DB Cluck","year":"2024","unstructured":"Cluck DB, Chastain DB, Murray M, Durham SH, Chahine EB, Derrick C, et al. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and\/or have multidrug-resistant HIV-1: endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy. Pharmacotherapy. 2024;44(5):360\u201382.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2181_CR173","doi-asserted-by":"crossref","first-page":"ofae125","DOI":"10.1093\/ofid\/ofae125","volume":"11","author":"M Gandhi","year":"2024","unstructured":"Gandhi M, Hill L, Grochowski J, Nelson A, Koss CA, Mayorga-Munoz F, et al. Case series of people with HIV on the long-acting combination of lenacapavir and cabotegravir: call for a trial. Open Forum Infect Dis. 2024;11(4):ofae125.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"2181_CR174","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/87551225241259894","volume":"40","author":"C Beran","year":"2024","unstructured":"Beran C, Duggan JM, Sahloff EG. A narrative review of novel agents for managing heavily treatment-experienced people living with HIV. J Pharm Technol. 2024;40(4):194\u2013201.","journal-title":"J Pharm Technol"},{"issue":"7","key":"2181_CR175","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","volume":"379","author":"B Emu","year":"2018","unstructured":"Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"2181_CR176","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1060028020942218","volume":"55","author":"EB Chahine","year":"2021","unstructured":"Chahine EB, Durham SH. Ibalizumab: the first monoclonal antibody for the treatment of HIV-1 infection. Ann Pharmacother. 2021;55(2):230\u20139.","journal-title":"Ann Pharmacother"},{"issue":"13","key":"2181_CR177","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","volume":"382","author":"M Kozal","year":"2020","unstructured":"Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med. 2020;382(13):1232\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"2181_CR178","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","volume":"19","author":"M Aboud","year":"2019","unstructured":"Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2181_CR179","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12879-024-09122-5","volume":"24","author":"M Heidary","year":"2024","unstructured":"Heidary M, Shariati S, Nourigheimasi S, Khorami M, Moradi M, Motahar M, et al. Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir. BMC Infect Dis. 2024;24(1):250.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2181_CR180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107009","volume":"63","author":"AM Hitchcock","year":"2024","unstructured":"Hitchcock AM, Kufel WD, Dwyer KAM, Sidman EF. Lenacapavir: a novel injectable HIV-1 capsid inhibitor. Int J Antimicrob Agents. 2024;63(1): 107009.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"2181_CR181","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkaa474","volume":"76","author":"M Gartland","year":"2021","unstructured":"Gartland M, Zhou N, Stewart E, Pierce A, Clark A, Ackerman P, et al. Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(R) Entry assay. J Antimicrob Chemother. 2021;76(3):648\u201352.","journal-title":"J Antimicrob Chemother"},{"key":"2181_CR182","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf050","author":"NA Margot","year":"2025","unstructured":"Margot NA, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen LA, Ling J, et al. Resistance analyses in heavily treatment-experienced people with HIV treated with the novel HIV capsid inhibitor lenacapavir after 2 years. J Infect Dis. 2025. https:\/\/doi.org\/10.1093\/infdis\/jiaf050.","journal-title":"J Infect Dis"},{"issue":"1","key":"2181_CR183","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/QAD.0000000000003097","volume":"36","author":"R Rose","year":"2022","unstructured":"Rose R, Gartland M, Li Z, Zhou N, Cockett M, Beloor J, et al. Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc. AIDS. 2022;36(1):11\u20138.","journal-title":"AIDS"},{"issue":"12","key":"2181_CR184","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","volume":"382","author":"S Swindells","year":"2020","unstructured":"Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112\u201323.","journal-title":"N Engl J Med"},{"key":"2181_CR185","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae557","author":"JM Davis","year":"2024","unstructured":"Davis JM, Rana A, Sax PE, Bares SH. Long-acting cabotegravir plus rilpivirine in people with HIV with adherence challenges and viremia: current data and future directions. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae557.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2181_CR186","first-page":"1060-1","volume":"331","author":"PE Sax","year":"2024","unstructured":"Sax PE, Thompson MA, Saag MS, Panel I-UTG. Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA Guidelines Panel. JAMA. 2024;331(12):1060\u20131.","journal-title":"JAMA"},{"key":"2181_CR187","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae500","author":"MD Hickey","year":"2024","unstructured":"Hickey MD, Gistand N, Grochowski J, Mayorga-Munoz F, Imbert E, Szumowski JD, et al. 48-week viral suppression rates in people with HIV starting long-acting CAB\/RPV with initial viremia. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae500.","journal-title":"Clin Infect Dis"},{"key":"2181_CR188","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae631","author":"A Perez Navarro","year":"2024","unstructured":"Perez Navarro A, Nutt CT, Siedner MJ, McCluskey SM, Hill A. Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long acting cabotegravir for HIV treatment: a meta-analysis. Clin Infect Dis. 2024. https:\/\/doi.org\/10.1093\/cid\/ciae631.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2181_CR189","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/09564624241288293","volume":"36","author":"KL O\u2019Neil","year":"2025","unstructured":"O\u2019Neil KL, Ching PR, Higginson RT, Pecora FP. Case series of two persons living with HIV with detectable viral loads initiated then suppressed on cabotegravir\/rilpivirine with lenacapavir. Int J STD AIDS. 2025;36(2):155\u20137.","journal-title":"Int J STD AIDS"},{"key":"2181_CR190","unstructured":"NIH. HIV\/AIDS Clinical Trials Networks. [cited 2025 January 21]. https:\/\/www.niaid.nih.gov\/research\/hivaids-clinical-trials-networks."},{"key":"2181_CR191","doi-asserted-by":"publisher","DOI":"10.2174\/0109298673306606240802111136","author":"KA dos Santos","year":"2024","unstructured":"dos Santos KA, de Carvalho Moreira LMC, Soares-Sobrinho JL, de LaRocaSoares MF. New horizons in antiretroviral drug delivery systems for HIV management. Curr Med Chem. 2024. https:\/\/doi.org\/10.2174\/0109298673306606240802111136.","journal-title":"Curr Med Chem"},{"key":"2181_CR192","unstructured":"CDC. National hiv prevention and care outcomes. 2024 [cited 2024 January 9]. https:\/\/www.cdc.gov\/hiv-data\/nhss\/national-hiv-prevention-and-care-outcomes.html#:~:text=In%202022%2C%20over%2080%25%20of,national%20goal%20of%20ending%20HIV."},{"key":"2181_CR193","unstructured":"UNAIDS. Understanding measures of progress towards the 95\u201395\u201395 HIV testing, treatment and viral suppression targets. [cited 2025 January 4]. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/progress-towards-95-95-95_en.pdf."},{"key":"2181_CR194","unstructured":"CDC. Fast Facts: HIV in the United States. [cited 2025 January 4]. https:\/\/www.cdc.gov\/hiv\/data-research\/facts-stats\/index.html."},{"issue":"14","key":"2181_CR195","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1097\/QAD.0000000000002679","volume":"34","author":"KL Bajema","year":"2020","unstructured":"Bajema KL, Nance RM, Delaney JAC, Eaton E, Davy-Mendez T, Karris MY, et al. Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. AIDS. 2020;34(14):2051\u20139.","journal-title":"AIDS"},{"issue":"10","key":"2181_CR196","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/cid\/ciw128","volume":"62","author":"AU Scherrer","year":"2016","unstructured":"Scherrer AU, von Wyl V, Yang WL, Kouyos RD, Boni J, Yerly S, et al. Emergence of acquired HIV-1 drug resistance almost stopped in Switzerland: a 15-year prospective cohort analysis. Clin Infect Dis. 2016;62(10):1310\u20137.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2181_CR197","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/hiv.12421","volume":"18","author":"S Teeraananchai","year":"2017","unstructured":"Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256\u201366.","journal-title":"HIV Med"},{"issue":"1","key":"2181_CR198","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/QAI.0000000000001014","volume":"73","author":"JL Marcus","year":"2016","unstructured":"Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr, Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39\u201346.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"2181_CR199","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/hiv.13591","volume":"24","author":"JM Trevillyan","year":"2023","unstructured":"Trevillyan JM, Behrens G. Ageing with HIV; a victory, a challenge and a call to action. HIV Med. 2023;24(12):1169\u201371.","journal-title":"HIV Med"},{"issue":"2","key":"2181_CR200","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/cid\/ciz178","volume":"70","author":"IA Abela","year":"2020","unstructured":"Abela IA, Scherrer AU, Boni J, Yerly S, Klimkait T, Perreau M, et al. Emergence of drug resistance in the Swiss HIV cohort study under potent antiretroviral therapy is observed in socially disadvantaged patients. Clin Infect Dis. 2020;70(2):297\u2013303.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2181_CR201","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1038\/s41467-024-47254-z","volume":"15","author":"SA Kemp","year":"2024","unstructured":"Kemp SA, Kamelian K, Cuadros DF, Consortium P, Vukuzazi T, Cheng MTK, et al. HIV transmission dynamics and population-wide drug resistance in rural South Africa. Nat Commun. 2024;15(1):3644.","journal-title":"Nat Commun"},{"issue":"1","key":"2181_CR202","doi-asserted-by":"crossref","first-page":"20798","DOI":"10.7448\/IAS.19.1.20798","volume":"19","author":"K Brooks","year":"2016","unstructured":"Brooks K, Diero L, DeLong A, Balamane M, Reitsma M, Kemboi E, et al. Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya. J Int AIDS Soc. 2016;19(1):20798.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"2181_CR203","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41591-023-02763-0","volume":"30","author":"J Fokam","year":"2024","unstructured":"Fokam J, Inzaule S, Colizzi V, Perno CF, Kaseya J, Ndembi N. HIV drug resistance to integrase inhibitors in low- and middle-income countries. Nat Med. 2024;30(3):618\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"2181_CR204","volume":"13","author":"SM Topp","year":"2018","unstructured":"Topp SM, Mwamba C, Sharma A, Mukamba N, Beres LK, Geng E, et al. Rethinking retention: mapping interactions between multiple factors that influence long-term engagement in HIV care. PLoS ONE. 2018;13(3): e0193641.","journal-title":"PLoS ONE"},{"issue":"7","key":"2181_CR205","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(18)30710-2","volume":"19","author":"SC Inzaule","year":"2019","unstructured":"Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infect Dis. 2019;19(7):e246\u201352.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"2181_CR206","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"RL Hamers","year":"2018","unstructured":"Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV. 2018;5(10):e588\u201396.","journal-title":"Lancet HIV."},{"key":"2181_CR207","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103896","volume":"77","author":"B Rodes","year":"2022","unstructured":"Rodes B, Cadinanos J, Esteban-Cantos A, Rodriguez-Centeno J, Arribas JR. Ageing with HIV: challenges and biomarkers. EBioMedicine. 2022;77: 103896.","journal-title":"EBioMedicine"},{"issue":"2","key":"2181_CR208","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","volume":"7","author":"A Chawla","year":"2018","unstructured":"Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183\u201395.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"2181_CR209","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11904-021-00547-0","volume":"18","author":"SF Sieg","year":"2021","unstructured":"Sieg SF, Shive CL, Panigrahi S, Freeman ML. Probing the interface of HIV and inflammaging. Curr HIV\/AIDS Rep. 2021;18(3):198\u2013210.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"4","key":"2181_CR210","first-page":"133","volume":"25","author":"JS Currier","year":"2018","unstructured":"Currier JS. Management of long-term complications of HIV disease: focus on cardiovascular disease. Top Antivir Med. 2018;25(4):133\u20137.","journal-title":"Top Antivir Med."},{"issue":"3","key":"2181_CR211","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2666-7568(21)00278-6","volume":"3","author":"M Montano","year":"2022","unstructured":"Montano M, Oursler KK, Xu K, Sun YV, Marconi VC. Biological ageing with HIV infection: evaluating the geroscience hypothesis. Lancet Healthy Longev. 2022;3(3):e194\u2013205.","journal-title":"Lancet Healthy Longev."},{"issue":"1","key":"2181_CR212","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cei.12814","volume":"187","author":"M Nasi","year":"2017","unstructured":"Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Ageing and inflammation in patients with HIV infection. Clin Exp Immunol. 2017;187(1):44\u201352.","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2181_CR213","first-page":"589","volume":"32","author":"K Sheets","year":"2024","unstructured":"Sheets K, Baker JV. HIV and inflamm-aging: how do we reach the summit of healthy aging? Top Antivir Med. 2024;32(5):589\u201396.","journal-title":"Top Antivir Med."},{"issue":"11","key":"2181_CR214","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","volume":"134","author":"LM Obare","year":"2024","unstructured":"Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circ Res. 2024;134(11):1515\u201345.","journal-title":"Circ Res"},{"issue":"6","key":"2181_CR215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MNH.0000000000001018","volume":"33","author":"N Wearne","year":"2024","unstructured":"Wearne N, Davidson B. HIV-associated kidney disease: the changing spectrum and treatment priorities. Curr Opin Nephrol Hypertens. 2024;33(6):603\u201312.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"11","key":"2181_CR216","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/QAD.0000000000003973","volume":"38","author":"EM King","year":"2024","unstructured":"King EM, Tkachuk S, Tseng A. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV. AIDS. 2024;38(11):1609\u201316.","journal-title":"AIDS"},{"issue":"3","key":"2181_CR217","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40266-022-01003-3","volume":"40","author":"P Sarma","year":"2023","unstructured":"Sarma P, Cassidy R, Corlett S, Katusiime B. Ageing with HIV: medicine optimisation challenges and support needs for older people living with HIV: a systematic review. Drugs Aging. 2023;40(3):179\u2013240.","journal-title":"Drugs Aging"},{"issue":"12","key":"2181_CR218","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/QAD.0000000000001870","volume":"32","author":"TG Harris","year":"2018","unstructured":"Harris TG, Rabkin M, El-Sadr WM. Achieving the fourth 90: healthy aging for people living with HIV. AIDS. 2018;32(12):1563\u20139.","journal-title":"AIDS"},{"issue":"1","key":"2181_CR219","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12877-024-04704-z","volume":"24","author":"SN Mbalinda","year":"2024","unstructured":"Mbalinda SN, Lusota DA, Muddu M, Nyashanu M. Ageing with HIV: challenges and coping mechanisms of older adults 50 years and above living with HIV in Uganda. BMC Geriatr. 2024;24(1):95.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2181_CR220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0898264317724549","volume":"31","author":"MJ Siedner","year":"2019","unstructured":"Siedner MJ. Aging, health, and quality of life for older people living with HIV in Sub-Saharan Africa: a review and proposed conceptual framework. J Aging Health. 2019;31(1):109\u201338.","journal-title":"J Aging Health"},{"issue":"8","key":"2181_CR221","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/09540121.2023.2190956","volume":"35","author":"TJ Barber","year":"2023","unstructured":"Barber TJ, Crabtree B, Cortes CP, Guaraldi G, Hoy JF, Rajasuriar R, et al. Practical management of complexity in older people with HIV: approaching an international consensus. AIDS Care. 2023;35(8):1149\u201353.","journal-title":"AIDS Care"},{"issue":"18","key":"2181_CR222","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMc086373","volume":"359","author":"BS Taylor","year":"2008","unstructured":"Taylor BS, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;359(18):1965\u20136.","journal-title":"N Engl J Med"},{"key":"2181_CR223","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020112","volume":"2","author":"R Kantor","year":"2005","unstructured":"Kantor R, Katzenstein D, Efron B, Carvalho AP, Wynhoven B, Soares M, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotypic evolution: results of a global collaboration. PLoS Med. 2005;2: e112.","journal-title":"PLoS Med"},{"issue":"9","key":"2181_CR224","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(19)30146-8","volume":"6","author":"B Grinsztejn","year":"2019","unstructured":"Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. Lancet HIV. 2019;6(9):e588\u2013600.","journal-title":"Lancet HIV."},{"issue":"11","key":"2181_CR225","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/QAD.0b013e32833ac7a2","volume":"24","author":"C Grunfeld","year":"2010","unstructured":"Grunfeld C, Saag M, Cofrancesco J Jr, Lewis CE, Kronmal R, Heymsfield S, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS. 2010;24(11):1717\u201326.","journal-title":"AIDS"},{"issue":"6","key":"2181_CR226","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1212\/01.wnl.0000203336.12114.09","volume":"66","author":"CL Cherry","year":"2006","unstructured":"Cherry CL, Skolasky RL, Lal L, Creighton J, Hauer P, Raman SP, et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology. 2006;66(6):867\u201373.","journal-title":"Neurology"},{"key":"2181_CR227","unstructured":"FDA. FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx\/Videx EC (didanosine). 2010 [cited 2024 January 7]. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fda-drug-safety-communication-serious-liver-disorder-associated-use-videxvidex-ec-didanosine."},{"issue":"4","key":"2181_CR228","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/ijerph19042359","volume":"19","author":"RA Roomaney","year":"2022","unstructured":"Roomaney RA, van Wyk B, Pillay-van Wyk V. Aging with HIV: increased risk of HIV comorbidities in older adults. Int J Environ Res Public Health. 2022;19(4):2359.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"2181_CR229","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3390\/biom12070894","volume":"12","author":"H Rudd","year":"2022","unstructured":"Rudd H, Toborek M. Pitfalls of antiretroviral therapy: current status and long-term CNS toxicity. Biomolecules. 2022;12(7):894.","journal-title":"Biomolecules"},{"issue":"4","key":"2181_CR230","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.kint.2022.06.021","volume":"102","author":"A Lucas","year":"2022","unstructured":"Lucas A, Wyatt CM. HIV at 40: kidney disease in HIV treatment, prevention, and cure. Kidney Int. 2022;102(4):740\u20139.","journal-title":"Kidney Int"},{"issue":"8","key":"2181_CR231","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","volume":"51","author":"HJ Stellbrink","year":"2010","unstructured":"Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963\u201372.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2181_CR232","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/COH.0000000000000614","volume":"15","author":"A Richterman","year":"2020","unstructured":"Richterman A, Sax PE. Antiretroviral therapy in older people with HIV. Curr Opin HIV AIDS. 2020;15(2):118\u201325.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"2181_CR233","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","volume":"38","author":"GA McComsey","year":"2021","unstructured":"McComsey GA, Lingohr-Smith M, Rogers R, Lin J, Donga P. Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States. Adv Ther. 2021;38(9):4961\u201374.","journal-title":"Adv Ther"},{"issue":"5","key":"2181_CR234","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11904-021-00568-9","volume":"18","author":"LB Whiteley","year":"2021","unstructured":"Whiteley LB, Olsen EM, Haubrick KK, Odoom E, Tarantino N, Brown LK. A Review of interventions to enhance HIV medication adherence. Curr HIV\/AIDS Rep. 2021;18(5):443\u201357.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2181_CR235","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"2181_CR236","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/13548506.2014.945601","volume":"20","author":"KR Claborn","year":"2015","unstructured":"Claborn KR, Meier E, Miller MB, Leffingwell TR. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol Health Med. 2015;20(3):255\u201365.","journal-title":"Psychol Health Med"},{"issue":"2","key":"2181_CR237","doi-asserted-by":"crossref","first-page":"e0263742","DOI":"10.1371\/journal.pone.0263742","volume":"17","author":"CT Tchakoute","year":"2022","unstructured":"Tchakoute CT, Rhee SY, Hare CB, Shafer RW, Sainani K. Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system. PLoS ONE. 2022;17(2):e0263742.","journal-title":"PLoS ONE"},{"issue":"1","key":"2181_CR238","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11904-018-0377-0","volume":"15","author":"JR Castillo-Mancilla","year":"2018","unstructured":"Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV\/AIDS Rep. 2018;15(1):49\u201359.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"2181_CR239","first-page":"102","volume":"26","author":"PRS Almeida","year":"2024","unstructured":"Almeida PRS, Rafael CAC, Pimentel V, Abecasis AB, Sebastiao CS, Morais J. Adherence to antiretroviral therapy among HIV-1 patients from sub-Saharan Africa: a systematic review. AIDS Rev. 2024;26(3):102\u201310.","journal-title":"AIDS Rev"},{"issue":"3","key":"2181_CR240","doi-asserted-by":"crossref","first-page":"dlae074","DOI":"10.1093\/jacamr\/dlae074","volume":"6","author":"T Clemente","year":"2024","unstructured":"Clemente T, Canetti D, Messina E, Carini E, Della Torre L, Papaioannu Borjesson R, et al. Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach. JAC Antimicrob Resist. 2024;6(3):dlae074.","journal-title":"JAC Antimicrob Resist."},{"key":"2181_CR241","doi-asserted-by":"publisher","DOI":"10.1177\/23259582211009011","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S. The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Int Assoc Provid AIDS Care. 2021. https:\/\/doi.org\/10.1177\/23259582211009011.","journal-title":"J Int Assoc Provid AIDS Care."},{"issue":"5","key":"2181_CR242","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10(5):e332\u201342.","journal-title":"Lancet HIV."},{"issue":"1","key":"2181_CR243","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/COH.0000000000000901","volume":"20","author":"Y Arens","year":"2025","unstructured":"Arens Y, Gulick RM. Future options for long-acting HIV treatment and prevention. Curr Opin HIV AIDS. 2025;20(1):39\u201347.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"2181_CR244","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COH.0000000000000710","volume":"17","author":"CW Flexner","year":"2022","unstructured":"Flexner CW, Kashuba A. Editorial: New drugs for HIV: quo vadis? Curr Opin HIV AIDS. 2022;17(1):1\u20133.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"2181_CR245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/COH.0000000000000904","volume":"20","author":"KA Christopoulos","year":"2025","unstructured":"Christopoulos KA, Hickey MD, Rana A. Use of long-acting injectable cabotegravir\/rilpivirine in people with HIV and adherence challenges. Curr Opin HIV AIDS. 2025;20(1):11\u20138.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"2181_CR246","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s10461-020-02822-4","volume":"24","author":"LK Reif","year":"2020","unstructured":"Reif LK, Abrams EJ, Arpadi S, Elul B, McNairy ML, Fitzgerald DW, et al. Interventions to improve antiretroviral therapy adherence among adolescents and youth in low- and middle-income countries: a systematic review 2015\u20132019. AIDS Behav. 2020;24(10):2797\u2013810.","journal-title":"AIDS Behav"},{"issue":"6","key":"2181_CR247","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40272-024-00656-4","volume":"26","author":"AEM Kamphuis","year":"2024","unstructured":"Kamphuis AEM, Bamford A, Tagarro A, Cressey TR, Bekker A, Amuge P, et al. Optimising paediatric HIV treatment: recent developments and future directions. Paediatr Drugs. 2024;26(6):631\u201348.","journal-title":"Paediatr Drugs"},{"key":"2181_CR248","unstructured":"WHO. Advanced HIV disease. [cited 2025 January 22]. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/treatment\/advanced-hiv-disease."},{"key":"2181_CR249","unstructured":"DHHS. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2024 [cited 2025 January 22]. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv\/introduction."},{"key":"2181_CR250","unstructured":"WHO. HIV data and statistics. [cited 2024 April 10]. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics."},{"key":"2181_CR251","unstructured":"UNICEF. Paediatric care and treatment. [cited 2024 July 14]. https:\/\/data.unicef.org\/topic\/hivaids\/paediatric-treatment-and-care\/."},{"issue":"10398","key":"2181_CR252","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(23)00860-7","volume":"402","author":"Child GBD, Adolescent Communicable Disease C","year":"2023","unstructured":"Child GBD, Adolescent Communicable Disease C. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990\u20132019: a systematic analysis of the Global Burden of Disease Study 2019. Lancet. 2023;402(10398):313\u201335.","journal-title":"Lancet"},{"key":"2181_CR253","volume":"77","author":"L Ge","year":"2024","unstructured":"Ge L, Luo Y, Li X, Hu Y, Sun L, Bu F, et al. Global, regional, and national prevalence of HIV-1 drug resistance in treatment-naive and treatment-experienced children and adolescents: a systematic review and meta-analysis. EClinicalMedicine. 2024;77: 102859.","journal-title":"EClinicalMedicine."},{"issue":"5","key":"2181_CR254","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1093\/jac\/dkac443","volume":"78","author":"GM Hunt","year":"2023","unstructured":"Hunt GM, Yousif M, Levin L, Ledwaba J, Steegen K, Kufa T, et al. Resistance is common in paediatric patients failing ART in South Africa. J Antimicrob Chemother. 2023;78(5):1160\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2181_CR255","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/QAI.0000000000002850","volume":"89","author":"W Nyandiko","year":"2022","unstructured":"Nyandiko W, Holland S, Vreeman R, DeLong AK, Manne A, Novitsky V, et al. HIV-1 treatment failure, drug resistance, and clinical outcomes in perinatally infected children and adolescents failing first-line antiretroviral therapy in Western Kenya. J Acquir Immune Defic Syndr. 2022;89(2):231\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"2181_CR256","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/QAI.0000000000003345","volume":"95","author":"EM Arnold","year":"2024","unstructured":"Arnold EM, Kamal S, Rotheram-Borus MJ, Bridges SK, Gertsch W, Norwood P, et al. Factors associated with antiretroviral adherence among youth living with HIV. J Acquir Immune Defic Syndr. 2024;95(3):215\u201321.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"2181_CR257","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1016\/S2352-3018(23)00118-2","volume":"10","author":"T Ruel","year":"2023","unstructured":"Ruel T, Mwangwa F, Balzer LB, Ayieko J, Nyabuti M, Mugoma WE, et al. A multilevel health system intervention for virological suppression in adolescents and young adults living with HIV in rural Kenya and Uganda (SEARCH-Youth): a cluster randomised trial. Lancet HIV. 2023;10(8):e518\u201327.","journal-title":"Lancet HIV."},{"issue":"5","key":"2181_CR258","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/QAI.0000000000003090","volume":"91","author":"P Nyakato","year":"2022","unstructured":"Nyakato P, Christ B, Anderegg N, Muhairwe J, Jefferys L, van Dijk J, et al. High unreported mortality in children and youth (<25 years) living with HIV who were lost to care from antiretroviral therapy programs in southern Africa: results from a multicountry tracing study. J Acquir Immune Defic Syndr. 2022;91(5):429\u201333.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"2181_CR259","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25759","volume":"24","author":"RC Vreeman","year":"2021","unstructured":"Vreeman RC, Rakhmanina NY, Nyandiko WM, Puthanakit T, Kantor R. Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV. J Int AIDS Soc. 2021;24(6): e25759.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"2181_CR260","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26041","volume":"26","author":"LJ Frigati","year":"2023","unstructured":"Frigati LJ, Gibb D, Harwell J, Kose J, Musiime V, Rabie H, et al. The hard part we often forget: providing care to children and adolescents with advanced HIV disease. J Int AIDS Soc. 2023;26(3): e26041.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"2181_CR261","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/COH.0000000000000880","volume":"19","author":"N Rakhmanina","year":"2024","unstructured":"Rakhmanina N, Foster C, Agwu A. Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here? Curr Opin HIV AIDS. 2024;19(6):368\u201376.","journal-title":"Curr Opin HIV AIDS"},{"issue":"7","key":"2181_CR262","volume":"27","author":"AH Sohn","year":"2024","unstructured":"Sohn AH, Davies MA. Adults with perinatally acquired HIV in low- and middle-income settings: time for a generational shift in HIV care and global guidance. J Int AIDS Soc. 2024;27(7): e26338.","journal-title":"J Int AIDS Soc"},{"issue":"11","key":"2181_CR263","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26191","volume":"26","author":"S Essajee","year":"2023","unstructured":"Essajee S, Bains A. Getting back on track to ending AIDS in children: it could just be easier than you think. J Int AIDS Soc. 2023;26(11): e26191.","journal-title":"J Int AIDS Soc"},{"key":"2181_CR264","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2016.10.004","volume":"53","author":"EJ Wing","year":"2016","unstructured":"Wing EJ. HIV and aging. Int J Infect Dis. 2016;53:61\u20138.","journal-title":"Int J Infect Dis"},{"key":"2181_CR265","first-page":"131","volume":"128","author":"EJ Wing","year":"2017","unstructured":"Wing EJ. The aging population with HIV infection. Trans Am Clin Climatol Assoc. 2017;128:131\u201344.","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"1","key":"2181_CR266","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/aid.2022.0079","volume":"39","author":"X Yu","year":"2023","unstructured":"Yu X, Lobo JD, Sundermann E, Baker DJ, Tracy RP, Kuchel GA, et al. Current challenges and solutions for clinical management and care of people with HIV: findings from the 12th Annual International HIV and Aging Workshop. AIDS Res Hum Retroviruses. 2023;39(1):1\u201312.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"2181_CR267","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3018(22)00003-0","volume":"9","author":"AC Justice","year":"2022","unstructured":"Justice AC, Goetz MB, Stewart CN, Hogan BC, Humes E, Luz PM, et al. Delayed presentation of HIV among older individuals: a growing problem. Lancet HIV. 2022;9(4):e269\u201380.","journal-title":"Lancet HIV."},{"issue":"8","key":"2181_CR268","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"2181_CR269","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/cid\/ciu779","volume":"60","author":"AK Monroe","year":"2015","unstructured":"Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis. 2015;60(3):453\u201362.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2181_CR270","first-page":"13","volume":"25","author":"CM Wyatt","year":"2017","unstructured":"Wyatt CM. Kidney disease and HIV infection. Top Antivir Med. 2017;25(1):13\u20136.","journal-title":"Top Antivir Med."},{"issue":"11","key":"2181_CR271","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","volume":"4","author":"RU Hernandez-Ramirez","year":"2017","unstructured":"Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA. Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV. 2017;4(11):e495\u2013504.","journal-title":"Lancet HIV."},{"issue":"7","key":"2181_CR272","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1158\/1055-9965.EPI-16-0964","volume":"26","author":"AE Coghill","year":"2017","unstructured":"Coghill AE, Pfeiffer RM, Shiels MS, Engels EA. Excess mortality among HIV-infected individuals with cancer in the United States. Cancer Epidemiol Biomark Prev. 2017;26(7):1027\u201333.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"2181_CR273","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266191","volume":"17","author":"F Branas","year":"2022","unstructured":"Branas F, Galindo MJ, Torralba M, Antela A, Vergas J, Ramirez M, et al. Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: the FUNCFRAIL cohort study (GeSIDA 9817). PLoS ONE. 2022;17(3): e0266191.","journal-title":"PLoS ONE"},{"issue":"2","key":"2181_CR274","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cger.2023.12.004","volume":"40","author":"ML Russell","year":"2024","unstructured":"Russell ML, Justice A. Human immunodeficiency virus in older adults. Clin Geriatr Med. 2024;40(2):285\u201398.","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"2181_CR275","first-page":"87","volume":"25","author":"J Navarro","year":"2022","unstructured":"Navarro J. HIV and liver disease. AIDS Rev. 2022;25(2):87\u201396.","journal-title":"AIDS Rev"},{"issue":"3","key":"2181_CR276","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/QAD.0000000000004057","volume":"39","author":"T Bennett","year":"2025","unstructured":"Bennett T, Walmsley S, Bendayan R. Aging with HIV and HIV-associated neurocognitive impairment. AIDS. 2025;39(3):215\u201328.","journal-title":"AIDS"},{"issue":"4","key":"2181_CR277","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1016\/S2352-3018(22)00009-1","volume":"9","author":"J Kiplagat","year":"2022","unstructured":"Kiplagat J, Tran DN, Barber T, Njuguna B, Vedanthan R, Triant VA, et al. How health systems can adapt to a population ageing with HIV and comorbid disease. Lancet HIV. 2022;9(4):e281\u201392.","journal-title":"Lancet HIV."},{"issue":"8","key":"2181_CR278","first-page":"368","volume":"24","author":"P Crits-Christoph","year":"2018","unstructured":"Crits-Christoph P, Gallop R, Noll E, Rothbard A, Diehl CK, Connolly Gibbons MB, et al. Impact of a medical home model on costs and utilization among comorbid HIV-positive Medicaid patients. Am J Manag Care. 2018;24(8):368\u201375.","journal-title":"Am J Manag Care"},{"issue":"3","key":"2181_CR279","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.idc.2019.04.005","volume":"33","author":"KM Erlandson","year":"2019","unstructured":"Erlandson KM, Karris MY. HIV and aging: reconsidering the approach to management of comorbidities. Infect Dis Clin North Am. 2019;33(3):769\u201386.","journal-title":"Infect Dis Clin North Am"},{"issue":"10","key":"2181_CR280","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25188","volume":"21","author":"EL Siegler","year":"2018","unstructured":"Siegler EL, Burchett CO, Glesby MJ. Older people with HIV are an essential part of the continuum of HIV care. J Int AIDS Soc. 2018;21(10): e25188.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"2181_CR281","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40262-023-01291-x","volume":"62","author":"T Toledo","year":"2023","unstructured":"Toledo T, Castro T, Oliveira VG, Veloso VG, Grinsztejn B, Cardoso SW, et al. Pharmacokinetics of antiretroviral drugs in older people living with HIV: a systematic review. Clin Pharmacokinet. 2023;62(9):1219\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2181_CR282","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40266-024-01168-z","volume":"42","author":"JF Hoy","year":"2025","unstructured":"Hoy JF. Individualizing antiretroviral therapy in the older patient. Drugs Aging. 2025;42(1):9\u201320.","journal-title":"Drugs Aging"},{"issue":"Suppl 1","key":"2181_CR283","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ggi.14717","volume":"24","author":"C Yang","year":"2024","unstructured":"Yang C, Teh YE, Chua NGS, Lee KLS, Ng RQM. An overview of multimorbidity and polypharmacy in older people living with HIV. Geriatr Gerontol Int. 2024;24(Suppl 1):49\u201359.","journal-title":"Geriatr Gerontol Int"},{"issue":"3","key":"2181_CR284","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/jgs.12695","volume":"62","author":"M Greene","year":"2014","unstructured":"Greene M, Steinman MA, McNicholl IR, Valcour V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014;62(3):447\u201353.","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"2181_CR285","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/phar.2043","volume":"37","author":"IR McNicholl","year":"2017","unstructured":"McNicholl IR, Gandhi M, Hare CB, Greene M, Pierluissi E. A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patients. Pharmacotherapy. 2017;37(12):1498\u2013506.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2181_CR286","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/hiv.12883","volume":"21","author":"B Lopez-Centeno","year":"2020","unstructured":"Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, Bellon JM, Perez-Latorre L, Lopez JC, et al. Potentially inappropriate medications in older adults living with HIV. HIV Med. 2020;21(8):541\u20136.","journal-title":"HIV Med"},{"issue":"2","key":"2181_CR287","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/COH.0000000000000608","volume":"15","author":"EJ Edelman","year":"2020","unstructured":"Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. Curr Opin HIV AIDS. 2020;15(2):126\u201333.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"2181_CR288","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1016\/S2666-7568(21)00206-3","volume":"2","author":"AC Justice","year":"2021","unstructured":"Justice AC, Gordon KS, Romero J, Edelman EJ, Garcia BJ, Jones P, et al. Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. Lancet Healthy Longev. 2021;2(10):e639\u201350.","journal-title":"Lancet Healthy Longev."},{"issue":"2","key":"2181_CR289","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25449","volume":"23","author":"D Back","year":"2020","unstructured":"Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc. 2020;23(2): e25449.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"2181_CR290","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1080\/09540121.2017.1281877","volume":"29","author":"B Milanini","year":"2017","unstructured":"Milanini B, Catella S, Perkovich B, Esmaeili-Firidouni P, Wendelken L, Paul R, et al. Psychiatric symptom burden in older people living with HIV with and without cognitive impairment: the UCSF HIV over 60 cohort study. AIDS Care. 2017;29(9):1178\u201385.","journal-title":"AIDS Care"},{"issue":"9","key":"2181_CR291","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/QAD.0000000000002227","volume":"33","author":"RH Remien","year":"2019","unstructured":"Remien RH, Stirratt MJ, Nguyen N, Robbins RN, Pala AN, Mellins CA. Mental health and HIV\/AIDS: the need for an integrated response. AIDS. 2019;33(9):1411\u201320.","journal-title":"AIDS"},{"issue":"Suppl 2","key":"2181_CR292","doi-asserted-by":"crossref","first-page":"e25705","DOI":"10.1002\/jia2.25705","volume":"24","author":"EK Too","year":"2021","unstructured":"Too EK, Abubakar A, Nasambu C, Koot HM, Cuijpers P, Newton CR, et al. Prevalence and factors associated with common mental disorders in young people living with HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2021;24(Suppl 2):e25705.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"2181_CR293","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1080\/09540120903280901","volume":"22","author":"C Grov","year":"2010","unstructured":"Grov C, Golub SA, Parsons JT, Brennan M, Karpiak SE. Loneliness and HIV-related stigma explain depression among older HIV-positive adults. AIDS Care. 2010;22(5):630\u20139.","journal-title":"AIDS Care"},{"issue":"7","key":"2181_CR294","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1176\/appi.ps.51.7.903","volume":"51","author":"SC Kalichman","year":"2000","unstructured":"Kalichman SC, Heckman T, Kochman A, Sikkema K, Bergholte J. Depression and thoughts of suicide among middle-aged and older persons living with HIV-AIDS. Psychiatr Serv. 2000;51(7):903\u20137.","journal-title":"Psychiatr Serv"},{"key":"2181_CR295","doi-asserted-by":"crossref","first-page":"1259290","DOI":"10.3389\/fpsyt.2024.1259290","volume":"15","author":"J Ji","year":"2024","unstructured":"Ji J, Zhang Y, Ma Y, Jia L, Cai M, Li Z, et al. People who living with HIV\/AIDS also have a high prevalence of anxiety disorders: a systematic review and meta-analysis. Front Psychiatry. 2024;15:1259290.","journal-title":"Front Psychiatry."},{"issue":"10","key":"2181_CR296","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/apc.2014.0079","volume":"28","author":"SK Schwarcz","year":"2014","unstructured":"Schwarcz SK, Vu A, Hsu LC, Hessol NA. Changes in causes of death among persons with AIDS: San Francisco, California, 1996\u20132011. AIDS Patient Care STDS. 2014;28(10):517\u201323.","journal-title":"AIDS Patient Care STDS"},{"key":"2181_CR297","unstructured":"UNAIDS. Integration of mental health and HIV interventions. [cited 2025 January 8]. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/integration-mental-health-hiv-interventions_en.pdf."},{"key":"2181_CR298","first-page":"1","volume":"6","author":"FH Hu","year":"2024","unstructured":"Hu FH, Liu P, Jia YJ, Ge MW, Shen LT, Xia XP, et al. Prevalence of mental health problems in people living with HIV: a systematic review and meta-analysis. Psychol Health Med. 2024;6:1\u201317.","journal-title":"Psychol Health Med"},{"issue":"1","key":"2181_CR299","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41598-023-30451-z","volume":"13","author":"P Arashiro","year":"2023","unstructured":"Arashiro P, Maciel CG, Freitas FPR, Koch GSR, da Cunha JCP, Stolf AR, et al. Adherence to antiretroviral therapy in people living with HIV with moderate or severe mental disorder. Sci Rep. 2023;13(1):3569.","journal-title":"Sci Rep"},{"issue":"3","key":"2181_CR300","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.idc.2024.06.003","volume":"38","author":"AJ Lier","year":"2024","unstructured":"Lier AJ, Tarfa A, Shenoi SV, Kuo I, Springer SA. HIV and substance use disorders. Infect Dis Clin North Am. 2024;38(3):599\u2013611.","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"2181_CR301","doi-asserted-by":"crossref","first-page":"E140","DOI":"10.9778\/cmajo.20140101","volume":"3","author":"J Gurm","year":"2015","unstructured":"Gurm J, Samji H, Nophal A, Ding E, Strehlau V, Zhu J, et al. Suicide mortality among people accessing highly active antiretroviral therapy for HIV\/AIDS in British Columbia: a retrospective analysis. CMAJ Open. 2015;3(2):E140\u20138.","journal-title":"CMAJ Open"},{"key":"2181_CR302","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.addbeh.2017.01.015","volume":"68","author":"S Shiau","year":"2017","unstructured":"Shiau S, Arpadi SM, Yin MT, Martins SS. Patterns of drug use and HIV infection among adults in a nationally representative sample. Addict Behav. 2017;68:39\u201344.","journal-title":"Addict Behav"},{"issue":"2","key":"2181_CR303","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1525-1497.2001.00122.x","volume":"16","author":"RL Cook","year":"2001","unstructured":"Cook RL, Sereika SM, Hunt SC, Woodward WC, Erlen JA, Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med. 2001;16(2):83\u20138.","journal-title":"J Gen Intern Med"},{"issue":"11","key":"2181_CR304","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s10461-018-2085-6","volume":"22","author":"CR Lesko","year":"2018","unstructured":"Lesko CR, Lau B, Chander G, Moore RD. Time spent with HIV viral load > 1500 copies\/mL among persons engaged in continuity HIV care in an urban clinic in the United States, 2010\u20132015. AIDS Behav. 2018;22(11):3443\u201350.","journal-title":"AIDS Behav"},{"issue":"1","key":"2181_CR305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3851\/IMP3265","volume":"24","author":"F Ladak","year":"2019","unstructured":"Ladak F, Socias E, Nolan S, Dong H, Kerr T, Wood E, et al. Substance use patterns and HIV-1 RNA viral load rebound among HIV-positive illicit drug users in a Canadian setting. Antivir Ther. 2019;24(1):19\u201325.","journal-title":"Antivir Ther"},{"issue":"5","key":"2181_CR306","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/hiv.12433","volume":"18","author":"CE Canan","year":"2017","unstructured":"Canan CE, Lau B, McCaul ME, Keruly J, Moore RD, Chander G. Effect of alcohol consumption on all-cause and liver-related mortality among HIV-infected individuals. HIV Med. 2017;18(5):332\u201341.","journal-title":"HIV Med"},{"issue":"5","key":"2181_CR307","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s11904-023-00667-9","volume":"20","author":"K Hill","year":"2023","unstructured":"Hill K, Kuo I, Shenoi SV, Desruisseaux MS, Springer SA. Integrated care models: HIV and substance use. Curr HIV\/AIDS Rep. 2023;20(5):286\u201395.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"1","key":"2181_CR308","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1186\/s12889-023-17113-5","volume":"23","author":"EV Pitpitan","year":"2023","unstructured":"Pitpitan EV, Wiginton JM, Bejarano-Romero R, Baker DA. Promoting HIV care continuum outcomes among people who use drugs and alcohol: a systematic review of randomized trials evaluating behavioral HIV care interventions published from 2011 to 2023. BMC Public Health. 2023;23(1):2182.","journal-title":"BMC Public Health"},{"issue":"3","key":"2181_CR309","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.idc.2019.04.006","volume":"33","author":"CM Bositis","year":"2019","unstructured":"Bositis CM, St LJ. HIV and substance use disorder: role of the HIV physician. Infect Dis Clin North Am. 2019;33(3):835\u201355.","journal-title":"Infect Dis Clin North Am"},{"key":"2181_CR310","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fpubh.2019.00094","volume":"7","author":"S Deren","year":"2019","unstructured":"Deren S, Cortes T, Dickson VV, Guilamo-Ramos V, Han BH, Karpiak S, et al. Substance use among older people living with HIV: challenges for health care providers. Front Public Health. 2019;7:94.","journal-title":"Front Public Health"},{"issue":"8","key":"2181_CR311","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S2215-0366(22)00159-6","volume":"9","author":"V Haldane","year":"2022","unstructured":"Haldane V, Jung AS, De Foo C, Shrestha P, Urdaneta E, Turk E, et al. Integrating HIV and substance misuse services: a person-centred approach grounded in human rights. Lancet Psychiatry. 2022;9(8):676\u201388.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"2181_CR312","doi-asserted-by":"crossref","first-page":"21585","DOI":"10.7448\/IAS.20.1.21585","volume":"20","author":"V Haldane","year":"2017","unstructured":"Haldane V, Cervero-Liceras F, Chuah FL, Ong SE, Murphy G, Sigfrid L, et al. Integrating HIV and substance use services: a systematic review. J Int AIDS Soc. 2017;20(1):21585.","journal-title":"J Int AIDS Soc"},{"key":"2181_CR313","unstructured":"CDC. Understanding the hiv care continuum. 2019 [cited 2021 November 14]. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/factsheets\/cdc-hiv-care-continuum.pdf."},{"key":"2181_CR314","unstructured":"UNAIDS. The HIV test-and-treat cascade. [cited 2024 July 14]. https:\/\/aids2020.unaids.org\/chapter\/chapter-2-2020-commitments\/the-hiv-test-and-treat-cascade\/."},{"issue":"9893","key":"2181_CR315","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700\u20138.","journal-title":"Lancet"},{"issue":"3","key":"2181_CR316","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","volume":"210","author":"A Castagna","year":"2014","unstructured":"Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354\u201362.","journal-title":"J Infect Dis"},{"issue":"2","key":"2181_CR317","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAI.0000000000001193","volume":"74","author":"GD Huhn","year":"2017","unstructured":"Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. A randomized, open-label trial to evaluate switching to elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide plus darunavir in treatment-experienced HIV-1-infected adults. J Acquir Immune Defic Syndr. 2017;74(2):193\u2013200.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"2181_CR318","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/15284336.2018.1550290","volume":"19","author":"AF Capetti","year":"2018","unstructured":"Capetti AF, De Socio GV, Cossu MV, Sterrantino G, Cenderello G, Cattelan A, et al. Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clin Trials. 2018;19(6):242\u20138.","journal-title":"HIV Clin Trials"},{"issue":"7","key":"2181_CR319","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3851\/IMP3330","volume":"24","author":"KL Hawkins","year":"2019","unstructured":"Hawkins KL, Montague BT, Rowan SE, Beum R, McLees MP, Johnson S, et al. Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals. Antivir Ther. 2019;24(7):513\u20139.","journal-title":"Antivir Ther"},{"issue":"11","key":"2181_CR320","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","volume":"7","author":"M Lataillade","year":"2020","unstructured":"Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):e740\u201351.","journal-title":"Lancet HIV."},{"issue":"3","key":"2181_CR321","volume":"58","author":"YL Lee","year":"2021","unstructured":"Lee YL, Lin KY, Cheng SH, Lu PL, Wang NC, Ho MW, et al. Dual therapy with dolutegravir plus boosted protease inhibitor as maintenance or salvage therapy in highly experienced people living with HIV. Int J Antimicrob Agents. 2021;58(3): 106403.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2181_CR322","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1093\/jac\/dkad285","volume":"78","author":"D Podzamczer","year":"2023","unstructured":"Podzamczer D, Imaz A, Lopez-Lirola A, Knobel H, Masia M, Fanciulli C, et al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF) plus darunavir\/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens. J Antimicrob Chemother. 2023;78(11):2696\u2013701.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2181_CR323","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1016\/S2352-3018(24)00089-4","volume":"11","author":"Group DES","year":"2024","unstructured":"Group DES. Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (D(2)EFT): an open-label, randomised, phase 3b\/4 trial. Lancet HIV. 2024;11(7):e436\u201348.","journal-title":"Lancet HIV"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02181-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02181-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02181-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T15:56:10Z","timestamp":1750694170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02181-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":323,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02181-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"26 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was partially funded by United States National Institutes of Health grants R01AI186632, K24AI134359, P30AI042853.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data supporting this manuscript are provided in it as well as in its citations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not relevant.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not relevant.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not relevant.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not relevant.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The paper was conceived by R.K. and written by all authors. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}